Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidne

What happened: Vertex announced that Phase 3 RAINIER results for povetacicept in IgA nephropathy were published in the New England Journal of Medicine and presented at ASN Kidney Week 2026. Key numbers: 52.0% reduction in proteinuria at Week 36; 49.8% reduction versus placebo (P<0.0001); 42.2% of treated participants reached UPCR <0.5 g/g versus 6.2% on placebo; FDA PDUFA date of November 30. Why it matters: Vertex says the data support best-in-class potential, and the company remains on track for a possible accelerated approval decision by the November 30 PDUFA date. Market: -2.1% today ($523.93), +15.9% YTD, 0.7x vol — as of 21:46 UTC

Vertex announced that Phase 3 RAINIER results for povetacicept in IgA nephropathy were published in the New England Journal of Medicine and presented at ASN Kidney Week 2026.

Vertex says the data support best-in-class potential, and the company remains on track for a possible accelerated approval decision by the November 30 PDUFA date. Market: -2.1% today ($523.93), +15.9% YTD, 0.7x vol — as of 21:46 UTC